View Document Preview and Link Document Date: 2015-01-29 05:49:27 Open Document File Size: 2,27 MB Share Result on Facebook
City Amsterdam / / Company Ingrid / Johnson & Johnson / Lilly / British Medical Journal / / Country United States / Netherlands / India / / Currency USD / / Event Product Recall / Product Issues / / Facility University Medical Center Utrecht / Utrecht University / VU University Medical Center / Utrecht Institute / / IndustryTerm pharmaceutical / / MedicalCondition pneumonia / Alzheimer’s disease / dementia / neurodegenerative disease / venous thrombosis / cardiovascular disease / disorientation / Druginduced parkinsonism / acute coronary syndrome / heart failure / massive pulmonary embolism / venous thromboembolism / delirium / restlessness / increased thrombosis / consequent pulmonary embolism / / MedicalTreatment pharmacotherapy / / Organization VU University Medical Center / Am Med Dir Assoc / Division of Pharmacoepidemiology and Clinical Pharmacology / FDA / EMGO / Geriatric Department of the University Medical Center Utrecht / Institute for Health and Care / Department of Nursing Home Medicine / Utrecht Institute for Pharmaceutical Sciences / Utrecht University / / Person Olanzapine / E.R. Heerdink / Bart Christiaan Kleijer / Ruth Daniëls / Schneider / Bart Christiaan Balancing / SURI GU / / Position Prime Minister / / Product Olanzapine / haloperidol / risperidone / study / / PublishedMedium the British Medical Journal / / RadioStation Waddinxveen FM / FR SURPRWRUHQ FM / Bart Kleijer FM / B.C. Kleijer FM / / Region western Europe / / SocialTag 
BALANCING THE BENEFITS AND RISKS OF ANTIPSYCHOTIC USE IN ELDERLY PATIENTS Bart Kleijer FM.indd 1